Comparison of patient and graft characteristics between trial patients and historic controls
| Characteristic . | Toci (n = 45) . | No Toci (n = 39) . | P value . |
|---|---|---|---|
| Age, median (range), y | 47 (27-60) | 47 (24-63) | .6 |
| Sex (male), n (%) | 21 (47%) | 19 (49%) | .9 |
| Weight (kg), median (range) | 79 (54-131) | 74 (49-114) | .4 |
| Ancestry, n (%) | .9 | ||
| European | 21 (47) | 18 (46) | |
| Non-European | 24 (53) | 21 (54) | |
| CMV serostatus, n (%) | .8 | ||
| Positive | 28 (62) | 24 (62) | |
| Negative | 14 (31) | 14 (36) | |
| Equivocal | 3 (7) | 1 (3) | |
| HCT-CI, n (%) | .11 | ||
| 0 | 17 (38) | 6 (15) | |
| 1 | 5 (11) | 9 (23) | |
| 2 | 8 (18) | 8 (21) | |
| ≥3 | 15 (33) | 16 (41) | |
| HCT-CI, median (range) | 2 (0-6) | 2 (0-6) | |
| aaHCT-CI, n (%) | .2 | ||
| 0 | 5 (11) | 2 (5) | |
| 1 | 14 (31) | 5 (13) | |
| 2 | 7 (16) | 11 (28) | |
| 3 | 6 (13) | 9 (23) | |
| ≥4 | 13 (29) | 12 (31) | |
| aaHCT-CI, median (range) | 2 (0-6) | 3 (0-7) | |
| Diagnosis, n (%) | .12 | ||
| AML | 21 (47) | 29 (74) | |
| ALL | 12 (27) | 4 (10) | |
| MPAL | 3 (7) | 1 (3) | |
| MDS | 4 (9) | 1 (3) | |
| CML | 2 (4) | 3 (8) | |
| NHL | 3 (7) | 1 (3) | |
| Cryopreserved TNC (per kg × 107 per unit), median (range)∗ | 2.81 (1.49-7.53) | 3.02 (1.54-8.07) | .4 |
| Cryopreserved CD34+ (per kg × 105 per unit), median (range)∗ | 2.26 (1.02-7.71) | 2.27 (1.11-8.34) | .8 |
| 8-allele HLA match∗ , n (%) | .5 | ||
| 3 | 10 (11) | 11 (14) | |
| 4 | 36 (40) | 25 (32) | |
| 5 | 34 (38) | 29 (37) | |
| 6 | 20 (22) | 11 (14) | |
| 7 | 0 (0) | 2 (3) |
| Characteristic . | Toci (n = 45) . | No Toci (n = 39) . | P value . |
|---|---|---|---|
| Age, median (range), y | 47 (27-60) | 47 (24-63) | .6 |
| Sex (male), n (%) | 21 (47%) | 19 (49%) | .9 |
| Weight (kg), median (range) | 79 (54-131) | 74 (49-114) | .4 |
| Ancestry, n (%) | .9 | ||
| European | 21 (47) | 18 (46) | |
| Non-European | 24 (53) | 21 (54) | |
| CMV serostatus, n (%) | .8 | ||
| Positive | 28 (62) | 24 (62) | |
| Negative | 14 (31) | 14 (36) | |
| Equivocal | 3 (7) | 1 (3) | |
| HCT-CI, n (%) | .11 | ||
| 0 | 17 (38) | 6 (15) | |
| 1 | 5 (11) | 9 (23) | |
| 2 | 8 (18) | 8 (21) | |
| ≥3 | 15 (33) | 16 (41) | |
| HCT-CI, median (range) | 2 (0-6) | 2 (0-6) | |
| aaHCT-CI, n (%) | .2 | ||
| 0 | 5 (11) | 2 (5) | |
| 1 | 14 (31) | 5 (13) | |
| 2 | 7 (16) | 11 (28) | |
| 3 | 6 (13) | 9 (23) | |
| ≥4 | 13 (29) | 12 (31) | |
| aaHCT-CI, median (range) | 2 (0-6) | 3 (0-7) | |
| Diagnosis, n (%) | .12 | ||
| AML | 21 (47) | 29 (74) | |
| ALL | 12 (27) | 4 (10) | |
| MPAL | 3 (7) | 1 (3) | |
| MDS | 4 (9) | 1 (3) | |
| CML | 2 (4) | 3 (8) | |
| NHL | 3 (7) | 1 (3) | |
| Cryopreserved TNC (per kg × 107 per unit), median (range)∗ | 2.81 (1.49-7.53) | 3.02 (1.54-8.07) | .4 |
| Cryopreserved CD34+ (per kg × 105 per unit), median (range)∗ | 2.26 (1.02-7.71) | 2.27 (1.11-8.34) | .8 |
| 8-allele HLA match∗ , n (%) | .5 | ||
| 3 | 10 (11) | 11 (14) | |
| 4 | 36 (40) | 25 (32) | |
| 5 | 34 (38) | 29 (37) | |
| 6 | 20 (22) | 11 (14) | |
| 7 | 0 (0) | 2 (3) |
Total infused units per group: Toci (n = 90), No Toci (n = 78).